It's that time of year again, and we are celebrating all things Mo with Paul Villanti, Executive Director at Movember. From its humble origins here in Melbourne 13 years ago, the Movember campaign has raised more than AUD$1.1bn over the past 13 years, funding more than 1250 projects around the world aimed at improving men's health. Quiet amazing, and a lot of fun. Prostate and testicular cancer have been particularly high priority areas for support, and we were keen to hear more of this and also to hear about the usual fun initiatives which Movember build into their campaigns.
Paul popped in to our studio to tell us about some of the highlights of this year's Movember, and to talk of some of the key initiatives which Movember support.
And what is a ChocoMo??? You'll have to tune in to find out!

Links:
Movember
ChocMo (courtesy of Dr Christian Wagner, Gronau, Germany) 

Today we focus on the NAVIGATE study,  a randomised trial of an online decision aid for men and their partners recently diagnosed with localised prostate cancer. Active surveillance is the preferred option for many men with low-risk prostate cancer, and may also be recommended for some men with favourable intermediate-risk prostate cancer, but many patients find the idea of surveillance to be stressful, and find the choice of management options to be bewildering. So today we chat with some of the team behind the NAVIGATE study which is designed to address some of these issues. NAVIGATE is running in Australia, sponsored by Swinburne University with the trial team based at Peter MacCallum Cancer Centre.
Joining us in studio are Natalie Richards who is a research nurse and NAVIGATE Project Manager, Alan White, patient representative on the project, and via Zoom is Dr Matt Roberts, a urologist in Brisbane who is actively enrolling patients. We also hear from a patient who is actively participating in the study and provides a terrific perspective having been on surveillance initially, and then went on to have surgery when his cancer changed while on surveillance. Your co-hosts are Declan Murphy and Renu Eapen from Peter Mac.
NAVIGATE is 80% recruited and is expected to finish recruitment in 2021. See below for details of how to find out more. Patients may be referred by their clinician or may self-refer directly to the NAVIGATE team if their cancer is suitable for surveillance. The Principal Investigator is Professor Penelope Schofield and the trial is funded by an NHMRC grant.

More info
NAVIGATE trial website
NAVIGATE info on Peter Mac website
Prostate Cancer Foundation of Australia

Regular GU Cast guest, Dr Ben Tran, joins us today to review some highlights from the recent virtual #ESMO20 Annual Meeting. Ben made headlines himself at this year's meeting as he presented his phase 1 study of AMG160 was selected for the prostate cancer plenary session (you got to tune in to hear him explain what a half-life extended bi-specific T cell engager is! Peter Mac Phase I and GU Fellow, Dr Ciara Conduit, also joins us to discuss this and other highlights including IPAT, PROfound, and the Checkmate 9ER study for mRCC. Usual hosts Declan Murphy and Renu Eapen. 

Exciting day today with the publication of the first edition of a brand new urology journal! And not one of those horrible predatory journals that we all get harassed by.
The Societe Internationale d'Urologie (SIU) is one of the leading organisations in urology and has a long history of partnering with other major journals to output their scientific content. It has now decided to publish its own journal, the SIU Journal, and today we were delighted to speak with their Editor-in-Chief, Professor Peter Black, from Vancouver and the University of British Columbia. Peter is very well known in the world of urology as a huge leader in GU Oncology, so it is very exciting to see him turn his talents to leading this journal. We are very confident himself and his very global editorial team will produce a fantastic journal. 

Links:
SIU Journal

Twitter
SIU Journal
SIU
Professor Peter Black

Today we join forces again with our good friends at the Prostate Cancer Foundation (PCF) to bring you the podcast version of the PCF Global Knowledge Exchange, this time focussing on Next Generation PSMA. Today's event is brought to you by PCF in conjunction with the Prostate Imaging and Theranostics Centre of Excellence (ProsTIC) at Peter MacCallum Cancer Centre in Melbourne. Your hosts are Dr Howard Soule and Dr Andrea Miyahira from the PCF, and Professor Michael Hofman and Professor Declan Murphy from ProsTIC.
PSMA imaging and theranostics are among the most exciting areas of research in prostate cancer, and today's event involves top leaders in the field who are tasked with looking beyond what we are using today. This PCF Global Knowledge Exchange is a full webinar which included more than 500 delegates from around the world, and we have posted the link to the YouTube version below. In the meantime, we hope that you might enjoy this podcast.

Speakers and topics include:
- Prof. Klaus Kopka: PSMA evolution
- Prof. Neil Bander: combination alpha-Ab / small molecule
- Dr Cristina Müller: Terbium PSMA
- Prof. Mike Sathekge: theranostics in low-mid income countries
- A/Prof Ana Kiess: auger-emitters to target micro-metastases
- Prof. John Babich: albumin-binding to increase uptake

Full webinar on Youtube
Click here

Links:
PCF
ProsTIC

Twitter:
PCF Science
ProsTIC
Peter Mac GU Onc

A big week for prostate cancer in the Lancet! No less than three much-anticipated randomised trials to investigate the role of adjuvant vs salvage radiotherapy in prostate cancer, were published in the Lancet and Lancet Oncology this week, plus a pre-planned meta-analysis of all three. RAVES, RADICALS-RT, and GETUG-AFU 17, each examined the issue of post-operative radiotherapy in men at risk of biochemical recurrence, and randomised those men to receive radiotherapy prior to PSA recurrence (adjuvant), or at the first sign of PSA recurrence (early salvage). There were some differences in patient population and trial design, but the overall message is that early salvage radiotherapy offers the same oncological benefit as adjuvant radiotherapy, with significantly less toxicity. An accompanying pre-planned meta-analayis (ARTISTIC), and Editorial reinforce the message.
GU Cast hosts Professor Declan Murphy and Dr Renu Eapen were delighted to speak today with RAVES lead author Professor Andrew Kneebone of Royal North Shore Hospital/University of Sydney, and co-author Professor Mark Frydenberg of Monash University, about the results of this trial and what it means for patients at risk of biochemical recurrence following radical prostatectomy. Truly practice-defining studies!

Links:
RAVES paper
RADICALS
GETUG-17
ARTISTIC meta-analysis
Lancet Editorial

TROG
ANZUP

Today we focus on trainee-led collaborative research, focussing on three of the best examples out there. We chat with the leaders of the British Urology Researchers in Surgical Training (BURST), the European Society of Residents in Urology (ESRU), and the Australian Young Urology Researchers Organisation (YURO). These groups have a number of missions, including networking and mentorship for trainees, but they also have a particular interest in collaborative research. We chat with Veeru Kasi and Meg Kulkarni from BURST, Diego Carrion Monsalve from ESRU, and Ellen O'Connor from YURO, about the beginnings of their respective organisations, how they function, their successes to date, and some of the challenges they face. We hear of some amazing examples of trainee-led research involving many thousands of patients, 50+ centres in multiple countries, with impressive publications to date. We also hear how organisations such as BAUS, EAU, and USANZ, and journals including BJUI, European Urology Today, and Minerva Urologica e Nefrologica have supported trainee-led research, but how more can be done to foster these initiatives.

Hosted by Declan Murphy and Renu Eapen from Peter MacCallum Cancer Centre.

Website Links:
BURST
ESRU
YURO

Twitter
BURST
ESRU
YURO
Veeru Kasi
Meg Kulkarni
Diego Carrion Monsalve
Ellen O'Connor

Others:
Join the BURST RESECT Study
BURST paper on communication in COVID era
Legends of Urology podcast

Continuing our season of chats with newly-minted Editors-in-Chief of top urology journals, today we chat with Dr Mike Leveridge of the Department of Urology, Queen's University, Ontario. Mike has just taken the reins as Editor-in-Chief of the Canadian Association of Urology (CUA) Journal, one of our favourite national journals, and has just published his opening editorial. CUA J is open access with no article processing fees - the rest of teh world should follow this example!!
One of our all time favourite friends in North America, and a great choice to lead this really useful journal. Usual hosts Declan Murphy and Renu Eapen are joined by colleague Nathan Lawrentschuk, who did Fellowship training with Mike in Toronto.

CUA Journal 
Mike's fantastic Twitter feed
Mike's debut editorial 

Uro-Twitterati legend Dr Ben Davies joins us today to trawl through his Twitter feed and share his wisdom on everything from tomatoes to leadership positions in Urology. Ben is Professor of Urology at the University of Pittsburgh, Chief of Urology at Shadyside/Hillman Cancer Centre and Director of the Uro-Oncology Fellowship Program. No holds barred chat with one of our favourite friends in Urology! With your usual hosts, Declan Murphy and Renu Eapen. 

Ben's Twitter feed https://twitter.com/daviesbj 

Professor Freddie Hamdy, Professor of Urology at the University of Oxford, has recently taken up the reigns as Editor-in-Chief of the British Journal of Urology International (BJUI) and has just published the first edition with his new editorial team. The BJUI has been around for more than 90 years and is one of the top journals in the world of urology. Its impact factor rose to an all-time high under the leadership of Prof Hamdy's predecessor. Professor Prokar Dasgupta, who also led a huge change to embrace digital and social media, and therefore Prof Hamdy takes over at an exciting time. 
Usual hosts Professor Declan Murphy (a past Associate Editor of BJUI) and Dr Renu Eapen (who recently joined the Editorial Board), are joined by Associate Professor Nathan Lawrentschuk who continues as Associate Editor in charge of the BJUI supplement.